(Q37996078)

26 August 2017

title

Induction therapy in renal transplant recipients: how convincing is the current evidence? (English)

1 reference

26 August 2017

Steven J Wagner

1

1 reference

26 August 2017

Daniel C Brennan

series ordinal

2

1 reference

26 August 2017

publication date

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

72

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

671-683

1 reference

Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Rabbit antithymocyte globulin induction therapy in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Immunotherapy: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Biological effects of induction immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

B-cell-depleting induction therapy and acute cellular rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Rabbit antithymocyte globulin versus basiliximab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Alemtuzumab induction in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Delayed graft function: risk factors and implications for renal allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Memory T-cell predominance following T-cell depletional therapy derives from homeostatic expansion of naive T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Immune reconstitution following rabbit antithymocyte globulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Long-term evolution of lymphocytes subsets after induction therapy based on continuous versus discontinuous administration of anti-thymocyte globulins in renal-transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

Identification of a B cell signature associated with renal transplant tolerance in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

BAFF is increased in renal transplant patients following treatment with alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631300-000000000-00000

A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients

21 January 2018

1 reference

12 December 2020

Intragraft Regulatory T Cells in Protocol Biopsies Retain Foxp3 Demethylation and Are Protective Biomarkers for Kidney Graft Outcome

1 reference

12 December 2020

Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

1 reference

12 December 2020

A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy

1 reference

12 December 2020

Lymphomas after solid organ transplantation: a collaborative transplant study report

1 reference

12 December 2020

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study

1 reference

12 December 2020

Long-term results of rabbit antithymocyte globulin and basiliximab induction

1 reference

12 December 2020

Forkhead box protein 3 mRNA expression in the peripheral blood of kidney-transplant recipients with acute rejection

1 reference

12 December 2020

KDIGO clinical practice guideline for the care of kidney transplant recipients

1 reference

12 December 2020

Acute rejection episodes--best predictor of long-term primary cadaveric renal transplant survival.

1 reference

12 December 2020

Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis

1 reference

12 December 2020

Impact of acute rejection and early allograft function on renal allograft survival

1 reference

12 December 2020

FOXP3+ regulatory T-cells in renal allografts: correlation with long-term graft function and acute rejection

1 reference

12 December 2020

Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation

1 reference

12 December 2020

Interleukin 2 receptor antagonists for kidney transplant recipients

1 reference

12 December 2020

Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation

1 reference

12 December 2020

Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model

1 reference

12 December 2020

CAMPATH IH ALLOWS LOW-DOSE CYCLOSPORINE MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS

1 reference

12 December 2020

10.2165/11631300-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1041183497

0 references

1 reference